BACKGROUND: Population-based studies suggest that, because of inequalities in treatment, black women with localized endometrial cancer have shorter survival compared with white women. The objective of the current investigation was to determine whether there is a racial disparity in outcome between black patients and white patients with early-stage endometrial cancer treated similarly in a clinical trial setting. METHODS: A retrospective review of 110 black patients and 1,049 white patients with stage I and II endometrial cancer (graded according to the International Federation of Gynecology and Obstetrics grading system) was performed using data from a randomized, placebo-controlled trial performed by the Gynecologic Oncology Group that evaluated postoperative estrogen replacement therapy (ERT) and the risk of cancer recurrence. Demographic, pathologic, treatment, and outcome-related data were collected and analyzed using regression and survival analysis. RESULTS: Estimates of recurrence-free survival suggested that black patients may be more likely to have disease recurrence, particularly those receiving ERT. Within a median follow-up of 3 years, 5 of 56 black patients with endometrial cancer in the ERT group were identified with recurrent disease compared with only 8 of 521 white patients. Adjusted for age, body mass index, and tumor grade, the relative risk of recurrence among blacks in the ERT group was 11.2 (95% confidence interval, 2.86-43.59; P = .0005). CONCLUSIONS: The findings of the current study suggested that recurrence-free survival may be shorter among black women with stage I endometrial cancer, even in a clinical trials setting in which patients receive similar treatment and follow-up. This increased risk of recurrence appeared to be most evident in black women with endometrial cancer who maintained ERT after primary treatment.
BACKGROUND: Population-based studies suggest that, because of inequalities in treatment, black women with localized endometrial cancer have shorter survival compared with white women. The objective of the current investigation was to determine whether there is a racial disparity in outcome between black patients and white patients with early-stage endometrial cancer treated similarly in a clinical trial setting. METHODS: A retrospective review of 110 black patients and 1,049 white patients with stage I and II endometrial cancer (graded according to the International Federation of Gynecology and Obstetrics grading system) was performed using data from a randomized, placebo-controlled trial performed by the Gynecologic Oncology Group that evaluated postoperative estrogen replacement therapy (ERT) and the risk of cancer recurrence. Demographic, pathologic, treatment, and outcome-related data were collected and analyzed using regression and survival analysis. RESULTS: Estimates of recurrence-free survival suggested that black patients may be more likely to have disease recurrence, particularly those receiving ERT. Within a median follow-up of 3 years, 5 of 56 black patients with endometrial cancer in the ERT group were identified with recurrent disease compared with only 8 of 521 white patients. Adjusted for age, body mass index, and tumor grade, the relative risk of recurrence among blacks in the ERT group was 11.2 (95% confidence interval, 2.86-43.59; P = .0005). CONCLUSIONS: The findings of the current study suggested that recurrence-free survival may be shorter among black women with stage I endometrial cancer, even in a clinical trials setting in which patients receive similar treatment and follow-up. This increased risk of recurrence appeared to be most evident in black women with endometrial cancer who maintained ERT after primary treatment.
Authors: G L Maxwell; J I Risinger; K A Hayes; A A Alvarez; R K Dodge; J C Barrett; A Berchuck Journal: Clin Cancer Res Date: 2000-08 Impact factor: 12.531
Authors: Timothy R Rebbeck; Andrea B Troxel; Yiting Wang; Amy H Walker; Saarene Panossian; Stephen Gallagher; Ekaterina G Shatalova; Rebecca Blanchard; Greta Bunin; Angela DeMichele; Stephen C Rubin; Mona Baumgarten; Michelle Berlin; Rita Schinnar; Jesse A Berlin; Brian L Strom Journal: J Natl Cancer Inst Date: 2006-09-20 Impact factor: 13.506
Authors: Terri Madison; David Schottenfeld; Sherman A James; Ann G Schwartz; Stephen B Gruber Journal: Am J Public Health Date: 2004-12 Impact factor: 9.308
Authors: G Larry Maxwell; Chunqiao Tian; John Risinger; Carol L Brown; G Scott Rose; J Tate Thigpen; Gini F Fleming; Holly H Gallion; Wendy R Brewster Journal: Cancer Date: 2006-11-01 Impact factor: 6.860
Authors: M F Kohler; P Carney; R Dodge; J T Soper; D L Clarke-Pearson; J R Marks; A Berchuck Journal: Am J Obstet Gynecol Date: 1996-11 Impact factor: 8.661
Authors: Christopher M Tarney; Chunqiao Tian; Guisong Wang; Elizabeth A Dubil; Nicholas W Bateman; John K Chan; Mohamed A Elshaikh; Michele L Cote; Joellen M Schildkraut; Craig D Shriver; Thomas P Conrads; Chad A Hamilton; G Larry Maxwell; Kathleen M Darcy Journal: Gynecol Oncol Date: 2017-08-08 Impact factor: 5.482
Authors: A S Felix; T M Brasky; D E Cohn; D G Mutch; W T Creasman; P H Thaker; J L Walker; R G Moore; S B Lele; S R Guntupalli; L S Downs; Ci Nagel; J F Boggess; M L Pearl; O B Ioffe; W Deng; D S Miller; L A Brinton Journal: Int J Cancer Date: 2017-11-06 Impact factor: 7.396
Authors: Ashley S Felix; Faina Linkov; G Larry Maxwell; Camille Ragin; Emanuela Taioli Journal: Int J Gynecol Cancer Date: 2011-02-01 Impact factor: 3.437